MedWatch

Biogen hopes for breakthrough at Danish Medicines Council after new price drop: "We have taken significant action"

In a video meeting on May 13, the Danish Medicines Council will discuss whether the use of drug Spinraza should be extended to a wider group of patients, after its creator Biogen has lowered the price significantly and new data has emerged.

Janne Harder, CEO of Biogen Denmark. | Photo: Biogen Danmark / PR

The Danish Medicines Council, which decides whether new medicines should be accepted for widespread use at Danish hospitals, will decide whether to expand the use of Spinraza (nusinersen) to more patients at a video meeting on May 13, the council reports.

The case is being reopened after Biogen, who markets Spinraza, lowered the price of the drug, which is currently used to treat patients with spinal muscular atrophy (SMA), and released new data about its effectiveness.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs